Clinical trials: Antipsychotic
Schizophrenia
Antipsychotic Augmentation With L-Dopa
Dopamine, a chemical in the brain, has been linked to schizophrenia for a number of years. More recently, there is evidence that certain areas affected in schizophrenia (e.g.
- Trial name
- NCT01636037
- Testing
- levodopa/carbidopa (generic version of Sinemet)
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia and Predominant Negative Symptoms
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predominant negative symptoms, as…
- Trial name
- NCT00922272
- Testing
- SPD489 (lisdexamfetamine dimesylate)
- Where
- 27 sites in United States
- Volunteers
- 92 people
- Sponsor
- Shire
Schizophrenia, Schizoaffective Disorder
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- SWITCHCore (NCT01143077)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 244 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs
Background: Antipsychotics can induce metabolic disorders such as obesity, hyperglycemia, dyslipidemia or metabolic syndrome. It has been observed that treatment with antipsychotic could be accompanied by a decrease in the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT02986490
- Testing
- Blood sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Schizophrenia
Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building
The purpose of this study was to investigate the effect of atypical antipsychotics on cardiac safety. The secondary purpose was to understand the rate of QTc prolongation in electrocardiogram induced by atypical antipsychotics.
- Trial name
- NCT04446234
- Testing
- Risperidone, Aripiprazole, Ziprasidone
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Shanghai Mental Health Center
Weight Gain
Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain
Lifestyle intervention and certain medications have been shown to be effective for antipsychotic-induced weight gain, but no controlled studies have compared psychological and pharmacological therapies.
- Trial name
- NCT00451399
- Testing
- metformin, lifestyle intervention
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Central South University
Psychosis
A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
Antipsychotic drugs are used to treat a range of psychiatric disorders including schizophrenia, bipolar disorders, and psychotic depression.
- Trial name
- MetaboMicrobe (NCT06729671)
- Testing
- Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsule, maltodextrin
- Where
- 2 sites in Ireland
- Volunteers
- 70 people
- Sponsor
- University College Cork
Dissociative Disorders, Schizophrenia
Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic
We propose a prospective multicenter study, whose originality lies in the inclusion of the naive child and adolescent population.
- Trial name
- NCT02007928
- Testing
- Rispéridone, aripiprazole, olanzapine
- Where
- 14 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Off-label Use of Atypical Antipsychotic Drugs
iADAPT: Off Label Use of Antipsychotics in the Nursing Home
The investigators propose to evaluate the effectiveness of 3 different methods to promote the dissemination and adoption of evidenced-based review guides into the nursing home setting.
- Trial name
- NCT01347619
- Testing
- Toolkit only with Web Access to Online Version, Toolkit, Periodic Audit/Feedback, Educational Messages, Items in Arm 2 plus Academic Detailing Program
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia, Schizoaffective Disorder
Clinical Estradiol Trial in Women With Schizophrenia
To investigate the 'estrogen-protection' hypothesis by comparing changes in psychotic symptoms between one group of patients receiving standard antipsychotic drug treatment plus placebo and a second matched group receiving…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00206570
- Testing
- Estradiol
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- Bayside Health
Schizophrenia
A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia
A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia and assess whether it changes: how the body processes (uses) glucose (blood sugar) how much…
- Trial name
- NCT05463770
- Testing
- SEP-363856
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of different dosages (from 3 mg/day to 12 mg/day) of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute…
- Trial name
- NCT00412373
- Testing
- Paliperidone ER
- Where
- 44 sites in United States, India and 4 more
- Volunteers
- 307 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Insulin Resistance, Dyslipidemia
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans
We hypothesized that short-term treatment with AP drugs induces insulin resistance through a mechanistic route that is independent of weight gain and that atypical drugs exert stronger effects than typical compounds in this…
- Trial name
- NCT00625170
- Testing
- olanzapine, Haloperidol
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Patient Noncompliance
Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%.
- Trial name
- CAE-L (NCT01152697)
- Testing
- haloperidol decanoate, haloperidol, Customized Adherence Enhancement
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia
The Phase I Study of HS-10509 in Chinese Adult Subjects
The study is to evaluate the safety, tolerability, and PK characteristics following single administration of HS-10509 in healthy adults, and multiple administrations of HS-10509 in patients with schizophrenia.
- Trial name
- NCT06301074
- Testing
- HS-10509
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- CAD (NCT00167310)
- Testing
- Eicosapentaenoic acid (omega-3 fatty acid)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Pittsburgh
Cognitive Impairment Associated With Schizophrenia
Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
To establish the proof of concept that MEM 3454, used as add-on pharmacotherapy, is a safe and effective treatment in patients with cognitive impairment associated with schizophrenia (CIAS).
- Trial name
- NCT00604760
- Testing
- MEM 3454
- Where
- 44 sites in United States
- Volunteers
- 160 people
- Sponsor
- Memory Pharmaceuticals
Schizophrenia
Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia
In a population of patients suffering from schizophrenia being treated for an episode of clinical destabilization and followed for a period of twelve months, the main objective is to evaluate the proportion of patients achieving…
- Trial name
- NCT02874560
- Where
- France
- Volunteers
- 364 people
- Sponsor
- Janssen-Cilag Ltd.
Obesity, Weight Gain
Reducing Antipsychotic-Induced Weight Gain in Children With Metformin
Recent but limited short term studies have shown that Metformin can slow down weight gain in obese children and in children with psychotropic-induced weight gain, two distinct pediatric populations that are at risk for obesity…
- Conditions
- Obesity, Weight Gain, Psychotropic Induced Weight Gain
- Trial name
- GFMS (NCT01231074)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Nationwide Children's Hospital
Diabetes
Examining the Effects of Antipsychotic Medications on Insulin Sensitivity
This study will examine the effects of two different antipsychotic medications on control of blood sugar in people who are at risk of diabetes but mentally healthy.
- Trial name
- NCT00895921
- Testing
- Olanzapine, Aripiprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation